alpha-chymotrypsin and Uveitis

Three hundred thirty-three eyes were randomly assigned to three treatments for cataract: group A, intracapsular extraction plus contact lens; group B, intracapsular extraction plus Federov implant (Federov I lenses were made by Rayners Ltd, United Kingdom, based on a design by Professor Fyodorov); and group C, extracapsular extraction plus iridocapsular implant. Endothelial cell loss estimated at one and six months and yearly up to four years showed significantly greater loss in the two implant groups from one year onward. Continuing loss slowed down after the third year, except for the intracapsular extraction plus implant group, in which cell loss appeared complication related. Of operative factors, use of alpha-chymotrypsin significantly reduced cell loss, and pseudophakos contact increased cell loss. Postoperative complications associated with significantly greater cell loss were hypopyon, uveitis, subluxation, shallow anterior chamber, and cystoid macular edema. To date, five and four cases of bullous keratopathy were derived from implant groups B and C, respectively.

Topics: Aged; Cataract Extraction; Cell Count; Chymotrypsin; Clinical Trials as Topic; Cornea; Endothelium; Humans; Lenses, Intraocular; Macular Edema; Middle Aged; Postoperative Complications; Random Allocation; Suppuration; Time Factors; Uveitis; Vitreous Body

Topics: Animals; Anti-Inflammatory Agents; Chymotrypsin; Clinical Trials as Topic; Eye Diseases; Humans; Indomethacin; Peptide Hydrolases; Rabbits; Uveitis

Limited proteolysis of bovine S-antigen with alpha-chymotrypsin resulted in the accumulation of three peptides of MW 24,000, 16,000, and 12,000 daltons, respectively. By ELISA (enzyme-linked immunosorbent assay), MW 24,000 peptide was found to react with anti-S antibodies, but the other two peptides did not react with the antibodies under the assay conditions. The reactive peptide was separated from the smaller peptides by gel filtration on Sephadex G-75 and Sephadex G-50. When the MW 24,000 peptide was injected into Lewis rats, severe to mild uveitis was produced in all injected animals. The results indicate that the pathogenic determinant is on the MW 24,000 peptide.

Topics: Animals; Antigens; Arrestin; Autoimmune Diseases; Chymotrypsin; Eye Proteins; Rats; Rats, Inbred Strains; Uveitis

Some premises on the clinical aspects of retinal detachment in patients operated upon for cataract and in conditions of lens dislocation are made. The different aspects of the preoperative prophylaxis (indications, techniques, application time) are dealt with, and the technical procedures used during operation for cataract are described. The authors point out the necessity of a postoperative control of the aphakic eyes, at short-or long-term in order to avoid vitreo retinal alterations.

Topics: Cataract Extraction; Chymotrypsin; Humans; Postoperative Complications; Retinal Degeneration; Retinal Detachment; Uveitis

Topics: Chymotrypsin; Humans; Recurrence; Trypsin; Uveitis

Topics: Animals; Cataract Extraction; Chymotrypsin; Fibrinolytic Agents; Methods; Peptide Hydrolases; Rabbits; Retinal Detachment; Uveitis; Vitreous Body; Wound Healing

Topics: Animals; Aqueous Humor; Biological Transport; Chymotrypsin; Ciliary Body; Iris; Penicillin G; Penicillin Resistance; Rabbits; Suppuration; Uveitis

Topics: Adolescent; Adult; Aged; Cataract; Cataract Extraction; Child; Chymotrypsin; Corneal Dystrophies, Hereditary; Corneal Opacity; Cryosurgery; Glaucoma; Humans; Middle Aged; Myopia; Surgical Instruments; Uveitis

Topics: Anti-Bacterial Agents; Arthritis; Arthritis, Rheumatoid; Cataract; Cataract Extraction; Chymotrypsin; Diabetes Mellitus; Drug Therapy; Endophthalmitis; Eye Diseases; Eye Foreign Bodies; Humans; Lens, Crystalline; Ophthalmia, Sympathetic; Panophthalmitis; Postoperative Complications; Steroids; Uveitis; Vitreous Body